Evidence map›Paper›PMID 27994981›Full record

ArticlePeerJ2016

One-year mortality after severe COPD exacerbation in Bulgaria.

Evgeni Mekov, Yanina Slavova, Adelina Tsakova, Marianka P Genova, Dimitar T Kostadinov, Delcho Minchev, Dora Marinova, Mihail A Boyanov

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Evgeni MekovClinical Center for Pulmonary Diseases, Medical University-Sofia , Sofia , Bulgaria.
Yanina SlavovaClinical Center for Pulmonary Diseases, Medical University-Sofia , Sofia , Bulgaria.
Adelina TsakovaDepartment of Clinical Laboratory and Clinical Immunology, Central Clinical Laboratory, Medical University-Sofia, University Hospital "Alexandrovska," Sofia , Bulgaria.
Marianka P GenovaDepartment of Clinical Laboratory and Clinical Immunology, Central Clinical Laboratory, Medical University-Sofia, University Hospital "Alexandrovska," Sofia , Bulgaria.
Dimitar T KostadinovClinical Center for Pulmonary Diseases, Medical University-Sofia , Sofia , Bulgaria.
Delcho MinchevClinical Center for Pulmonary Diseases, Medical University-Sofia , Sofia , Bulgaria.
Dora MarinovaClinical Center for Pulmonary Diseases, Medical University-Sofia , Sofia , Bulgaria.
Mihail A BoyanovDepartment of Internal Medicine, Clinic of Endocrinology and Metabolism, Medical University-Sofia, University Hospital "Alexandrovska," Sofia , Bulgaria.
Medical University of Sofia · BGSofia University "St. Kliment Ohridski" · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOne-year mortality in COPD patients is reported to be between 4% and 43%, depending on the group examined.

aimTo examine the one-year mortality in COPD patients after severe exacerbation and the correlation between mortality and patients' characteristics and comorbidities.

methodsA total of 152 COPD patients hospitalized for severe exacerbation were assessed for vitamin D status, diabetes mellitus (DM), arterial hypertension (AH), and metabolic syndrome (MS). Data were gathered about smoking status and number of exacerbations in previous year. CAT and mMRC questionnaires were completed by all patients. Pre- and post-bronchodilatory spirometry was performed. One-year mortality was established from national death register.

resultsOne-year mortality is 7.2%. DM, MS, and VD are not predictors for one-year mortality. However there is a trend for increased mortality in patients with AH (9.5% vs. 2.1%,

conclusionsThis study finds relatively low one-year mortality in COPD patients after surviving severe exacerbation. Grade C and FEV1 > 80% may be factors for good prognosis. Risk factors for increased mortality are age, FEV1 value, severe exacerbation in previous year and reduced quality of life.

Indexed as

ComorbiditiesCOPDExacerbationLung functionMortalityQuality of life

Identifiers

PMID27994981
PMCPMC5157192
OpenAlexW2564760932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.